
AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strikethrough~~ and additions are underlined.

Listing of Claims:

1. (Currently amended) A cancer gene therapeutic drug including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from the ~~following (1) to (4) cells:~~ group consisting of (1) A549 cell, (2) SW626 cell, and (3) HT-3 cell.
2. (Currently amended) The cancer gene therapeutic drug according to claim 1, wherein the oncolytic virus to be infected to the carrier cell has a promoter selected from the group consisting of 1A1.3B promoter, midkine promoter, β -HCG promoter, SCCA1 promoter, cox-2 promoter, PSA promoter~~or another~~ and a tumor specific promoter; according to ~~a kind of cancer to be treated etc.~~
3. (Currently amended) The cancer gene therapeutic drug according to claim 1 ~~or 2~~, wherein the virus for immunological treatment and the oncolytic virus are selected from the group consisting of adenovirus, herpes virus, lentivirus, such as HIV virus, retrovirus, reovirus, vesicular stomatitis virus (VSV) and any other oncolytic viruses.
4. (Original) The cancer gene therapeutic drug according to claim 1, further comprising a virus for immunological treatment to be administered for inducing a CTL reaction within the living body to administration of the carrier cell.
5. (Original) The cancer gene therapeutic drug according to claim 1, further comprising atelocollagen.

6. (Original) The cancer gene therapeutic drug according to claim 1, further comprising a GM-CSF expression vector to be infected to the carrier cell before administration.
7. (Original) The cancer gene therapeutic drug according to claim 1, further comprising an iron preparation and/or a porphyrin compound.
8. (Original) The cancer gene therapeutic drug according to claim 1, further comprising a tumor cell to be administered for tumor vaccination.
9. (Previously Amended) A cancer gene therapeutic drug including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein both A549 cell and 293 cell are together used as the carrier cell.
10. (New) The cancer gene therapeutic drug according to claim 2, wherein the virus for immunological treatment and the oncolytic virus are selected from the group consisting of adenovirus, herpes virus, lentivirus, HIV virus, retrovirus, reovirus, vesicular stomatitis virus (VSV) and any other oncolytic virus.